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Background: The production process for the current influenza vaccine takes about 6 months and its antigenic
composition must be modified annually. In the attempt towards developing influenza vaccine production that
would be faster, safer and cheaper we engineered an influenza vaccine in which multiple copies of hemagglutinin
(HA) would be delivered by a vector, adenovirus dodecahedron (Ad Dd). Dd is a virus-like particle, formed by
assembly of twelve copies of pentameric penton base (Pb) proteins responsible for virus penetration. In order to
attach HA to the vector, an adaptor containing WW domains was used. The WW domain is a linear peptide
fragment identified as a partner of proline-proline-x-tyrosine (PPxY) motif present at the N-terminal extremity of the
Pb protein, which is a building block of Dd. That tandem of three WW domains in fusion with the protein of
interest enables interaction with Dd and efficient translocation to the cytoplasm of cells in culture.
Results: Since HA is an oligomeric protein with complicated processing, we prepared six different constructs of HA
(A/swan/Poland/467/2006(H5N1)) in fusion with the WW adaptor. Herein we report baculovirus expression and functional
analysis of six HA-WW variants. The best behaving variant was successfully delivered into human cells in vitro.
Conclusions: Engineering of a soluble complex of HA with Dd, a virus-like particle that serves as a vector, an adjuvant
and as a multivalent presentation platform, is an important step toward a novel influenza vaccine.
Keywords: Influenza vaccine, Hemagglutinin, Adenovirus dodecahedron, WW-domain adaptor, Vaccine presentation
platform, MultivalencyBackground
The production process for the three influenza vaccines
approved by US Food and Drug Administration (FDA)
takes about 6 months and their antigenic composition
must be modified annually. They are prepared according
to a somewhat antiquated technology, known for the last
60 years. The virus is grown in fertilized hens eggs, and the
infected allantoic fluid is harvested. The extracted virus is
purified, inactivated and treated to produce a vaccine.
Multiple attempts are being described towards
developing influenza vaccine production that would
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reproduction in any medium, provided the orbased on subunit vaccines obtained through expression in
heterologous systems. Various prototypes produced in a
baculovirus-insect cell expression system have proven safe
and effective in clinical studies [1-6]. All subunit influenza
vaccines contain the influenza surface glycoprotein, HA,
one of the major protein constituents of the influenza
virus. HA induces the formation of neutralizing anti-
bodies, creating a first blockage against viral infection
[7,8] and it appears that protection provided by the
trivalent influenza virus vaccine is mediated primarily by
anti-HA neutralizing antibodies [7-9]. Influenza-infected
cells produce the HA precursor, HA0, that trimerizes in
the endoplasmic reticulum and is transferred through the
Golgi apparatus to the cell surface. Proteolytic cleavage
generates a trimeric HA protein, each monomer of which
consists of two disulfide-linked polypeptides: HA1 that
contains the receptor binding- and major antigenic sites,
and HA2 containing the fusion peptide. Both cleaved andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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but cleavage is an absolute requirement for membrane
fusion activity. Molecular weight of HA monomer ranges
from 70 to 84 kDa, depending on influenza virus serotype
([10] and references therein).
The final aim of our project is construction of a vaccine
complex that contains influenza antigens delivered by
adenovirus dodecahedron (Dd) acting as a vector, adjuvant
and a multivalent presentation platform. Adenovirus
Dd is a virus-like particle, formed by spontaneous
assembly of twelve adenovirus serotype 3 (Ad3) penton
base (Pb) proteins responsible for virus penetration [11].
Dodecahedra are devoid of genetic information, and form
a multivalent platform where the antigen can be presented
in multiple copies; their utility as delivery platform for
vaccinal antigens has already been shown [12,13]. In
this communication we describe the vaccine component
containing the HA antigen.
In order to attach HA to the vector, an adaptor
containing so-called WW domains is here used. WW
domain, a fragment of 23–35 amino acids flanked by
two tryptophans (W), is a partner of the proline-
proline-x-tyrosine (PPxY) motif present at the N-terminal
extremity of the penton base protein, Dd building block
[14]. A tandem of three WW domains, when cloned in
fusion with the protein of interest, acts as an adaptor
attaching this protein to Dd, which permits its efficient
translocation into the cytoplasm of cells in culture [15].
We have already used the WW linker in order to attach
an antigen to the dodecahedron, which resulted in massive
transfer of the noncovalent complex of vector with the
antigen to dendritic cells [12]. Furthermore, intracellular
Dd induced activation of dendritic cells. Finally, the Dd
carrying antigen underwent efficient capture, processing
and presentation by the dendritic cells (op.cit.).
Herein we report baculovirus expression and functional
analysis of six HA-WW variants in fusion with the
WW adaptor. The best behaving variant was successfully
delivered into human cells in vitro. Engineering of a soluble
complex of HA with Dd, a virus-like particle that serves as
a vector, an adjuvant and as a multivalent presentation plat-
form, is an important step toward a novel influenza vaccine.
Methods
Hemadsorption
HF cells expressing HAWW and WWHA proteins
corresponding to 200 μl culture were suspended in PBS,
distributed to wells of the 96-well microtiter plate and
sequentially diluted with PBS. Next, 10 μl of 1% hen
erythrocyte suspension was added to each well and the
plate was incubated for 1 h at room temperature.
Hemadsorption was observed under light microscope
(Olympus CK, magnification 20000 x) and photographs
were taken with Olympus C3040 camera.Hemagglutination
Aliquots of protein expressing HF cells (500 μl culture)
were suspended in 100 μl of hypotonic buffer, lysed by
freeze-thawing, dispensed to U-bottom 96-well microtiter
plate and diluted with the hypotonic buffer, as described
above. Next, 50 μl of 5% suspension of hen erythrocytes
was added to each well and the plate was incubated for
1 h at room temperature. Hemagglutination was inspected
visually and the plate was photographed.
Analysis of HA cell surface expression
Aliquots (500 μl culture) of live expressing HF at 48 h
post infection were incubated with anti-HA antibody
(100 μl, 1:100 in PBS; 1 h at 37°C) followed by incubation
with anti-rabbit FITC-labeled antibody (100 μl, 1:250 in
PBS; 1 h at 37°C). Simultaneously, similar aliquots of HF
cells were treated for 5 min on ice with trypsin (Sigma, 1 μg
per 500 μl cell portion) and the reaction was terminated by
addition of the Complete protease inhibitor. Portions of
approximately 10000 cells were analyzed by flow cytometry
on a FACSCalibur (Beckton Dickinson).
Overlay with dodecahedra
Lysates of expressing HF cells were separated on 10%
polyacrylamide gel, with BSA as a negative control and
WW protein as a positive control. Proteins were then
transferred onto PVDF membrane (Millipore) and incu-
bated for 2 h at RT with Dd preparation (25 μg/ml in
20 mM Tris pH 7, containing 150 mM NaCl, 2 mM EDTA,
5% glycerol) [16]. After 1 h blocking with 5% nonfat dried
milk in TBST, the membrane was incubated with anti-Dd
antibody (1:40000 in TBST) and anti-rabbit-HRP secondary
antibody (1: 100000) and revealed with the ECL reaction.
WW control protein was obtained from pGEX-4-T1
bearing WW 1,2,3 (Rsp5) gene by expression in bacteria
and purification on affinity column, using GST tag as
described in ref. [12].
Interaction of non-denatured HA variants with Dd, in
ELISA format
ELISA plate (Nunc) was coated with Dd solution of
100 μg/ml (2.5 μg/well), blocked with 0.3% BSA in PBS
(100 μl/well, 1 h, 37°C). HAWW- and WWHA-expressing
HF cells from 200 μl culture were pelleted and suspended
in HEPES buffer pH 7, serially diluted with the same buffer
and placed in wells of 96-well dish. After 1.5 h incubation
with gentle shaking at RT, the wells were washed with 0.3%
BSA in PBS and anti-HA primary antibody was added
(1:100, 50 μl per well). The plate was incubated for 1 h at
37°C and, after rinsing, with the secondary anti-rabbit
HRP-conjugated antibody (1:10000, 50 μl/well, 1 h at 37°C).
Wells were washed 3 times with 0.3% BSA in PBS and the
reaction was revealed with 3,3′,5,5′-tetramethylbenzidine
(Sigma-Aldrich), followed by immediate blocking with 1 N
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BIO-TEK Synergy HT fluorimeter.
Internalization of HAWW_5 in complex with Dd
HAWW_5-expressing HF cells were lysed for 5 min at
room temperature with Cytobuster (Novagen) (150 μl per
1 × 106 cells). The resultant lysate was incubated with the
dodecahedra for 1 h at RT to allow for the formation of the
Dd-HAWW_5 complex, and applied onto HeLa cells
grown on coverslips. After 60 min internalization, the cells
were rinsed with sterile PBS, permeabilized and fixed for
30 min in cold methanol. After another wash, the cells were
incubated with 5% BSA in PBS, and then with primary
anti-Dd antibody at 1:1000 or anti-HA antibody at 1:100,
each for 1 h at 37°C. Texas Red-labelled anti-rabbit
antibody was used at 1:250 dilution as the secondary
antibody and cell nuclei were stained with DAPI
(1 μg/ml, Pierce). The coverslips were attached to slides
using Mowiol (Sigma).
Results
Protein engineering, cloning, expression and visualization
In our initial studies on attachment to Dd we used three
tandem WW domains of human protein Nedd4 [14]. In
order to avoid potential induction of the autoimmune
response, we now use WW1,2,3 domains (here calledA
B
Figure 1 Hemagglutinin constructs in fusion with WW linker. (A) Sche
constructs. WWHA_1 and WWHA_2 contain the complete HA0 gene. Three co
domains. WWHA_3 and HAWW_4 contain HA1 and HA2 domains only, whileWW) of the yeast Rsp5 protein, that have been shown
to have comparable affinity to Dd [12]. Six different
constructs of hemagglutinin with N or C-terminally
positioned WW domains were prepared (primers are
shown in Additional file 1: Table S1). Some clones are
devoid of transmembrane (TM) domain and cytoplasmic
tail (CT) or/and signal peptide (SP) (Figure 1).
In order to ensure correct folding and oligomerization,
recombinant proteins were expressed in the baculovirus
system (Additional file 2). Preliminary SDS-PAGE
analysis of transfected insect cells confirmed correct
selection of positive recombinant clones and successful
transfection (Additional file 3: Figure S1), with the titers of
recombinant baculovirus ranging from 0.48 to 4 × 108
(Additional file 4: Table S2). Analysis of kinetics of protein
expression resulted in setting up the optimal expression
time at 48 h post infection. The successful expres-
sion of HA variants in HF cells was observed by
confocal microscopy (Additional file 5: Figure S3). It
has been shown by Li et al. [17] that deletion of the
transmembrane and cytoplasmic domains of HA
might result in secreted HA form. However, only
traces of HA proteins were observed in the cell
medium of three proteins, HAWW_3, HAWW_4
and HAWW_5, that were devoid of TM and cytoplasmic
domains (not shown).CT
CT
CT
matic representation of HA precursor gene. (B). Diagrams of HA
nstructs have N-terminally and three – C-terminally positioned WW
HAWW_5 is devoid of TM and CT domains, and WWHA_6 is devoid of SP.
Figure 2 Functional analysis of HA variants. (A) Hemadsorption assay. Protein expressing HF cells were incubated with a suspension of hen
red blood cells and hemadsorption was observed under light microscope. Non-expressing cells and dilution buffer were used as controls.
(B) Hemagglutination. Lysates of cells expressing proteins were serially diluted and incubated with erythrocytes as described in Materials and
Methods. Hemagglutination is shown by a uniform pink suspension of erythrocytes, while the lack of hemagglutination is accompanied by
appearance of a red dot in the middle of the well, corresponding to sedimented erythrocytes. Non-expressing HF cells and dillution buffer were
used as controls. Arrows indicate dilutions where specific hemagglutination was observed.
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Figure 3 Surface expression of recombinant proteins,
estimated by FACScan analysis. Black bars show mean fluorescence
of live expressing insect cells after incubation with anti-HA antibody.
Gray bars represent fluorescence values detected after trypsin treatment.
The relative signal decrease (in %) is shown above grey bars.
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Two clones, HAWW_2 and HAWW_5, produced proteins
that ran as about 15 kDa larger than expected and than
other HA proteins (Additional file 3: Figure S1 and
Additional file 4: Table S2), which suggested glycosylation.
Indeed, when the most interesting protein (see further),
HAWW_5, was treated with deglycosylation enzymes,
its mobility diminished, indicating removal of glycans
(Additional file 6: Figure S4).
Protein extraction
Four different extraction conditions were tested: sonication,
freeze-thawing and incubation with Cytobuster and Proteo
Jet. The HAWW_5 protein appeared to be the most soluble
variant in all tested extraction methods (lanes 5 in
Additional file 7: Figure S2). Proteins WWHA_3 and
HAWW_4 showed moderate solubility when extracted by
sonication, freeze-thawing or with Proteo Jet lysing solution.
WWHA_1, HAWW_2 and WWHA_6, all of which contain
transmembrane domains, could not be extracted under any
of these conditions. The combination of freeze-thawing and
incubation with Cytobuster did not improve this situation
(not shown).
Hemadsorption and hemagglutination
Whole or lysed HF cells were tested for their ability to
adsorb hen erythrocytes (hemadsorption test) and trigger
their agglutination. Very apparent hemadsorption was
observed for HAWW_2 and HAWW_5 (Figure 2A),
suggesting external membrane HA expression for these
clones. Hemagglutination – a uniform pink suspension
in microtiter plate - was observed for all variants of
the recombinant protein as well as for control cells
with no HA expression, when cells were diluted at
1:1 to 1:16. However, HAWW_2 and HAWW_5 revealed
specific hemagglutination at higher dilutions - 1:32 to
1:128 (Figure 2B, between arrows). This suggests that only
cells expressing HAWW_2 and HAWW_5 produced func-
tional HA. However, in view of the different solubility of
the six HA variants, this result may also reflect different
accessibility of HAWW/WWHA proteins for erythrocytes.
Localization of expressed proteins in HF cells
FACSscan analysis with anti-HA antibody in conjunction
with proteolysis was employed to investigate the
localization of HAWW and WWHA proteins in living
HF cells. In parallel, cells were treated with trypsin and
subsequently analyzed by Facscan, in order to analyse
protein accessibility to the protease (Figure 3). The
HAWW_5 variant appears to be the most abundantly
expressed on the insect cell surface and most susceptible
to proteolytic removal. Also WWHA_1 and HAWW_2
showed significant signal decrease upon trypsin treatment.
It is relevant that together with HAWW_5 these clonescontain the signal peptide (SP), known to mediate protein
transport to the insect cell surface.
Interaction with dodecahedron
Proteins containing WW fusions readily interact with
dodecahedra [12,13,15]. Since this interaction of WW
domains with the PPxY motif of Dd is essential in
our vaccine design, we tested HAWW and WWHA
proteins for this function. When cell extracts containing
SDS-denatured variants of HA were incubated with Dd, all
denatured recombinant proteins were able to attach to the
vector as detected with anti-Dd antibody (Figure 4A). In
the second approach, untreated expressing HF cells were
incubated with dodecahedra immobilized in wells of micro-
titer plate. When formation of a vector–recombinant pro-
tein complex was revealed with the anti-HA antibody, only
HAWW_5 efficiently bound to dodecahedron (Figure 4B),
which confirms the correct folding of this HA fusion variant
and its accessibility in live insect cells.
Internalization of HAWW_5 in complex with Dd in HeLa
cells
The analysis of the recombinant HAWW and WWHA
proteins permitted selection of one variant, HAWW_5,
with an appropriate structure and function (Table 1).
In order to demonstrate that the antigen is efficiently
internalized through its attachment to the vector, we
used confocal microscopy technique (Additional file 8:
Figure S5). Analysing vector and antigen co-localization
by using different secondary antibodies was not possible
due to the rabbit origin of both the anti-Dd and anti-HA
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Figure 4 Interaction of recombinant HAWW/WWHA proteins
with Dd. (A) Interaction of denatured HA variants. Proteins were
separated by SDS-PAGE, transferred to PVDF membrane and overlaid
with the Dd solution. Vector bound to the membrane was detected
with specific anti-Dd antibody. Lanes 1 to 6: WWHA_1 to WWHA_6,
respectively. K - control HF cells, WW – fragment of Rsp5 protein,
containing WW linker (positive control), BSA – bovine serum albumin
(negative control). Fusions of HA with WW are denoted with a dot. (B)
Interaction of non-denatured HA variants. Serial dilutions of HF cells
expressing HAWW/WWHA variants were incubated with Dd and the
recombinant proteins bound to the vector were detected with anti-HA
antibody as described in Materials and Methods.
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anti-HA antibody in cells incubated in the presence of the
complex compared to lack of the signal in control cells
incubated with the same antibody confirmed that the
antigen was introduced to cells by the dodecahedricTable 1 Properties of HA variants
WWHA_1 HAWW_2
WW position N-term C-term
Deletion
Solubility
Hemadsorption +
Hemagglutination +
Surface expression + ++
Interaction with Dd (overlay) + +
Interaction with Dd (ELISA) - -vector. No internalization was observed when cells were
incubated with HAWW_5 alone.
Co-expression of HAWW_5 with Dd
Attempts at isolation of significant amounts of HAWW_5
from expressing cells were unsuccessful. Therefore we tried
a strategy enabling simultaneous synthesis of Dd and
HAWW_5 from a dual-expression baculovirus. This strat-
egy furnished a soluble complex of Dd and HAWW_5,
which could be recovered from the heavy fractions of
a sucrose density gradient (Figure 5A and B, fractions
7–12). However, the synthesis that occurred at the 1: 1
ratio of appropriate genes led to a large excess of free Dd.
We therefore tried the co-expression of the Dd-HAWW_5
complex from two separate baculoviruses, which per-
mitted cell infection at the 10-fold excess of the
HAWW_5-expressing baculovirus. The resulting prepar-
ation contained much smaller amount of Dd (not shown),
with HAWW_5 that localized in the heavy sucrose fractions
containing Dd (Figure 5C, fractions 7–12). Approximately a
third part of the HA-antibody-reactive material consisted of
a full-length HAWW_5. The lower band is most probably
HA2WW, as it still migrates in heavy sucrose together with
Dd. The HA1, which is devoid of Dd-interacting WW
domain, appears in light sucrose (left part of Figure 5C). It
is of interest that HAWW_5 undergoes proteolytic process-
ing immediately upon expression, as shown in lane of
control HAWW_5 of Figure 5B. Another smaller fragment
of HA (marked with question mark) still contains the WW
domain, as it localized to heavy sucrose, which indicates its
ability to associate with Dd.
Discussion
Since it has been demonstrated that protection provided by
traditional vaccine is mediated primarily by anti-HA
neutralizing antibodies [8], it is plausible to think that simi-
lar results could be obtained by vaccination with the recom-
binant HA protein. Therefore, our approach for obtaining
induction of humoral influenza immunity consists of con-
struction of a vaccine complex expressed in the baculovirus
system that is composed of dodecahedric platform bearingWWHA_3 HAWW_4 HAWW_5 WWHA_6
N-term C-term C-term N-term
SP, TM, CT SP, TM. CT TM, CT SP
+ + ++
+
+
++ ++ +++ -
+ + + +
- - + -
AB
C 1 2   3  4 5 6 7   8 9 1 0  11 12
Anti-HA
(HA1) (HA2WW)
?
15% 40%
M 1  2 3   4   5 6 7   8 9 10 11 12
protein
Anti-HA
95
72
55
43
?
95
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kDa
Figure 5 Formation of soluble Dd-HAWW complexes in insect
cells. (A, B) HF cells were infected with the baculovirus co-expressing
Dd and HAWW_5 at MOI 5 or (C) by the baculoviruses expressing Dd
and HAWW_5 separatel. After 48 h cells were collected and lysed in
hypotonic buffer. Clarified lysates were fractionated on 15–40% sucrose
density gradients. Gradient fractions were resolved by SDS-PAGE and
transferred onto PVDF membrane. The position of HAWW_5 is indicated
by dots. (A) Proteins were stained with Ponceau S or (B) revealed
with anti-HA antibody. M – molecular weight markers, lanes 1 to
12 – gradient fractions. (C) Insect cells were infected with the
recombinant baculoviruses at a ratio of 1 (Dd) to 10 (HAWW_5). Proteins
were analyzed as above by Western blot performed with anti-HA
antibody. Full length HAWW_5 is marked with a black dot, tentative
HA2WW and HA1 are in brackets and the unknown HAWW fragment is
marked with question mark.
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the vector acts as a multivalent delivery platform for antigen
presentation as well as an adjuvant. We have previously
shown that the complex of Dd with antigen is a potent acti-
vator of human myeloid dendritic cells (MDC), and that it
is efficiently presented by MDC to antigen-specific CD8+ T
lymphocytes [12]. HA protein is here attached externally to
the vector through an adaptor containing WW domains
recognizing the PY motif present at the N-terminal extrem-
ity of Ad3 penton bases that are the Dd building blocks. It
is conceivable that use of this multivalent VLP, withremarkable cell penetration ability as well as adjuvant
properties, able to present multiple (up to 60) copies of an
antigen will permit humoral response achieved at low
amount of antigen. It is relevant that the critical function of
multimerization of the presentation platform in the
immunogenicity of influenza vaccine has already been
demonstrated [18]. In addition, symmetric oligomeric
VLP formed from the hepatitis B core protein is used
as a presentation platform for numerous vaccinal epitopes,
including influenza [19].
In the present study we constructed and characterized six
variants of HAWW and WWHA proteins. The WWHA_3
variant was not properly folded since it did not display a
hemagglutination function, in contrast to the HAWW_2
and HAWW_5 proteins. The main difference seems
to be the site of WW linker attachment (N-terminus
for WWHA_3 versus C-terminus for HAWW_2 and
HAWW_5), which suggests that fusion of the WW
domain at the N-terminal position is deleterious to
HA folding. It is possible that HAWW_5 protein behaved
better than HAWW_2 due to the lack of transmembrane
domain TM in HAWW_5. Indeed, only the HAWW_5
protein when non-denatured was able to interact with the
vector, showing that it is properly folded, functional and
might be a good starting material for influenza vaccine
construction. Initially we planned the separate expression
and isolation of Dd and HAWW_5 followed by in vitro
formation of vaccine complex. However, despite following
several published protocols for HA purification, we
were unable to recover a significant amount of soluble
HAWW_5 protein, conceivable due to the presence of the
WW linker.
In the next step, by constructing a baculovirus bearing
simultaneously genes for both HAWW_5 and Pb, we
attempted to obtain a soluble Dd-HAWW_5 complex
directly upon co-expression in insect cells. This resulted
in formation of a soluble complex, but with a significant
excess of free Dd, suggesting a low occupancy with
HAWW_5. Finally, co-expression of two proteins from
separate baculoviruses was attempted, in order to be
able to manipulate the ratio of infecting baculoviruses.
The final soluble complex contained a much smaller
amount of Dd. We believe, that this approach might lead
to influenza vaccine entirely prepared in cell culture.
Conclusions
In conclusion, our results suggest the following features
of future influenza vaccine:
A)The vaccine should contain an influenza antigen
proven to elicit immunity against influenza.
B) The antigen is delivered on a platform of a
multivalent, biocompatible and biodegradable vector
that was shown to induce maturation of human
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immune system adjuvant – hence, there would be no
need to use synthetic, potentially harmful adjuvants.
C) The vaccine is produced entirely in insect cells
(baculovirus system), which shortens the production
cycle and prevents induction of allergic reactions.
Engineering of a soluble complex of HA with Dd, a
virus-like particle that serves as a vector, an adjuvant and
as a multivalent presentation platform, is an important
step toward a novel influenza vaccine. It would make the
vaccine production much safer, cheaper and significantly
shorten the time necessary for its preparation.Additional files
Additional file 1: Table S1. Primers and restriction enzymes used for
constructing clones of HA in fusion with WW linker.
Additional file 2: Supplementary material.
Additional file 3: Figure S1. Analysis of recombinant protein
expression. HF cells were infected with the appropriate recombinant
baculoviruses, harvested 48 hours post infection, separated on SDS-PAGE
and stained with CBB. Lanes 1 to 6: WWHA_1, HAWW_2, WWHA_3,
HAWW_4, HAWW_5 and WWHA_6 clones, respectively. K- nonexpressing
HF cells. M – molecular weight markers, the values are given in kDa.
Additional file 4: Table S2. Analysis of expression.
Additional file 5: Figure S3. The successful expression of HA variants
in HF cells was observed by confocal microscopy.
Additional file 6: Figure S4. Deglycolysation of the recombinant
protein WWHA_5. Deglycosylation was carried out as described in
Materials and Methods. Deglycosylated (+) and non-treated (-) samples
were resolved by SDS-PAGE and analyzed by western blot performed
with anti-HA antibody.
Additional file 7: Figure S2. Extraction of recombinant proteins. HF
cells expressing HAWW and WWHA proteins were incubated with (A)
BugBuster, (B) ProteoJet, (C and D) hypotonic Tris buffer and additionally
subjected to sonication (C) or freeze/thawing (D). Western blot analysis of
supernatants and pellets was performed with anti-HA antibody as
described in Materials and Methods. Lanes 1 to 6: WWHA_1 to WWHA_6
clones, respectively. K- control HF cells.
Additional file 8: Figure S5. Visualization of the recombinant HAWW
and WWHA proteins. Expressing insect cells were analyzed with laser
scanning confocal microscopy. Recombinant proteins were detected with
anti–HA antibody labeled with Texas Red. Nuclei were stained blue with
DAPI. Left-side images show single confocal scans averaged 4 times,
whereas Nomarski images are shown on the right. Scale bar corresponds
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Table 1, Suppl. Mat. 
 
Primers and restriction enzymes used for constructing clones of HA in fusion with WW linker 
 
 
Construct Primers        Restriction 
           Site 
 
WWHA   F-CAGGGCATATGGAGAAAATAGTGC    NdeI, SphI 
 R-AACTCGCATGCTTAAATGCAAAT 
 
HAWW   F-GGTAAGCTCGAGAAATGGAGAAAATAGTGC   XhoI, NheI 
 R-GAACGCTAGCATAGAAATGCAAATTCTGC 
 
WWHA(SP
-
TM
-
)F-CCATCATCGCTAGACCATATGAGTGATCAGATTTGCATTGG NdeI, SphI 
 R-GCGTTGCATGCTATTGGTAGGTTCCTATTG 
 
HA(SP
-
TM
-
)WW F-CAGCCTCGAGATGAGTGATCAGATTTGC    XhoI, NheI 
 R-CAGGTGCTAGCTGGTAGGTTCCTATTG 
 
HA(TM
-
)WW  F-GGTAAGCTCGAGAAATGGAGAAAATAGTGC   XhoI, NheI 
 R-CAGGTGCTAGCTGGTAGGTTCCTATTG 
 
WWHA(SP
-
)  F-CCATCATCGCTAGACCATATGAGTGATCAGATTTGCATTGG NdeI, SphI 
 R-GCGTTGCATGCTATTGGTAGGTTCCTATTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Material 
 
Materials and methods 
Reagents. The plasmids pGEX-4T-1 (GE Healthcare), pGemEasy (Promega) 
and pFastBacDual (Invitrogen) were used. Restriction enzymes, ligase and PCR 
reactants were from Fermentas. The following antibodies were used: anti-HA 
(National Influenza Center, Lyon), anti-Dd (rabbit polyclonal serum prepared in our 
laboratory), and the secondary anti-rabbit HRP-conjugated and anti-rabbit Texas 
Red-conjugated antibodies (both from Jackson ImmunoResearch, Europe). Media 
used for insect cell cultures of Spodoptera frugiperda (Sf) and Trichoplusia ni (High-
Five, HF) were TC 100 and Express Five, respectively (both from Invitrogen), and for 
human HeLa cells - EMEM supplemented with 10% fetal bovine serum (FBS) (both 
from Lonza, Switzerland). 
 
Protein cloning and expression.  
Recombinant baculoviruses with HA variants. Fragment specifying WW1,2,3 
domains (subsequently called WW) from yeast Rsp5 protein and originally provided 
in pGEX-4T-1, was moved to empty pFastBacDual and cloned under control of p10 
promoter. For this, appropriate DNA containing NheI and SphI (PaeI) restriction sites 
was synthesized by PCR using forward primer: 
CTTCGCTAGCATTCTTACCCCCTGGTTGG and reverse primer: 
CACGAGCATGCCGCTACATATGGTCTAGCGATGATGG (restriction sites shown in 
bold) and cloned in NheI and SphI sites of pFastBacDual. HA0 precursor gene 
(A/swan/Poland/467/2006(H5N1), Epiflu database, accession no EPI156821) was 
provided in pGemEasy and cloned upstream of the WW insert between XhoI and 
NheI sites or downstream of the WW insert between NdeI and SphI sites. Six 
different constructs were designed (Fig. 1) and the appropriate couples of primers 
were used to synthesize the respective inserts (Table 1, Suppl. Mat.). The PCR 
products were digested with NdeI and SphI or with XhoI and NheI, respectively, and 
ligated to linearized WW gene. 
Baculoviruses expressing HA antigen and dodecahedron. For simultaneous 
expression of HA and Dd, pFastBacDualPb plasmid carrying Ad3 wt penton base 
gene (GenBank acc. no ABB17799.1) under the control of the polyhedrin promoter 
was used. The sequence coding for HAWW_5 fusion was excised with XhoI and 
SphI restriction enzymes from pFastBacDual bearing HAWW_5 fusion and ligated to 
XhoI and SphI linearized pFastBacDualPb, downstream of the p10 promoter. The 
recombinant plasmids containing HAWW_5 and Ad3 Pb genes were used to prepare 
baculoviruses expressing simultaneously or separately WWHA and Dd.  All plasmids 
were transfected to competent DH 10 Bac E. coli cells. Positive clones were 
identified by PCR, then the Sf21 cells were transfected with the bacmid DNA 
following standard Invitrogen protocol. The harvested virus was amplified and the 
titer of baculoviral stock was determined by plaque assay. For protein expression HF 
insect cells (2x106 cells/ml) growing in suspension were infected with the 
recombinant baculoviruses at multiplicity of infection (MOI) 5 and cultured at 27oC. 
Aliquots of each culture taken at different times post-infection were analyzed by 
Western blot with anti-HA primary antibody at 1:200 and anti-rabbit HRP-conjugated 
secondary antibody at 1:100 000. The ECL reaction was developed with Sigma 
reagents, using the Currix 60 AGFA apparatus. 
 
Protein extraction and analysis. HF cells expressing HAWW and WWHA fusion 
proteins were harvested at 48h and suspended in 20mM HEPES buffer, pH 7, 
supplemented with Complete protease inhibitor (Roche). Aliquots corresponding to 
200µl culture were harvested and cell pellets were resuspended in hypotonic buffer 
(20mM Tris pH 7, containing 50mM NaCl and 2mM EDTA) or Cytobuster lysing 
solution (Novagen) or Proteo Jet lysis solution (Fermentas). For Bug Buster and 
Proteo Jet extractions, the suspensions were incubated for 30min at RT, whereas the 
suspension in hypotonic buffer was divided in two parts and either sonicated or 
frozen-thawed four times. In some cases three cycles of freezing and thawing of the 
expressing cell pellets were applied to liberate the recombinant protein. All 
suspensions were centrifuged and supernatants and pellets were analyzed by 
Western blot. Proteins were detected with anti-HA antibody. HF cells co-expresing 
HAWW_5 and Dd were collected at 48h and lysed in hypotonic buffer supplemented 
with Complete protease inhibitor. Clarified lysates were fractionated on 15–40% 
sucrose density gradients as described before [17] and analysed by Western blot 
with anti-HA antibody. 
 
 Analysis of HA expression by confocal microscopy. Expressing HF cells 
were harvested 48h post-infection and suspended in HEPES buffer, pH 7, 
supplemented with Complete protease inhibitor. Aliquots corresponding to 200µl 
culture were recovered by centrifugation and cells were washed with PBS and fixed 
with cold methanol for 2h at -20°C. After 3 washes with PBS, cells were placed onto 
coverslips and left overnight to dry under laminar hood. Coverslips were blocked with 
5% BSA in PBS for 45min at RT and then incubated with anti-HA antibody (1:100 in 
PBS; 1h at 37°C) followed by anti rabbit-Texas Red antibody at 1:1000 in PBS for 1h 
at 37°C. Nuclei were stained with DAPI (1μg/ml, Pierce) and cells were rinsed again 
with PBS before mounting the coverslips on slides. The cells were observed with 
laser scanning confocal microscopy (Nikon) and images were collected with EZ-C1 
Nikon CLSM attached to an inverted microscope Eclipse TE2000 E (Nikon) using oil 
immersion objective x 60. Images show single confocal scans averaged four times, 
with pixel dwell time of 10µs. Photographs were processed using EZ-C1 Free Viewer 
software (Nikon). 
Deglycosylation. Cells expressing HAWW_5 (0.5ml) were suspended in 50µl of 
denaturing buffer, provided with the New England Biolabs deglycosylation kit, and 
incubated for 10min at 100oC. Next, 3 µl of the Peptide:N-Glycosidase (PNGase), 4µl 
of 10-fold concentrated reaction buffer and 3µl of NP-40 were added to the reaction 
mixture and deglycosylation was carried out for 10min. at 37oC. The incubation 
mixture was fractionated by SDS-PAGE and analyzed by Western blot with anti-HA 
antibody at 1:200 dilution.  
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Table 2, Suppl. Mat.  
 
Analysis of expression 
 
 
Construct Deletion Theoretical  Band on  Virus titer 
    MW, kDa SDS-PAGE,     x108 
      MW, kDa 
 
WWHA1  -   86,7    ~80    0.48  
HAWW2  -   86,7   >95   3.25  
WWHA3  SP,  TM- 81,3    ~80    4.00  
HA4WW  SP, TM-, 81,0    ~80    0.75  
HA5WW TM   82,8    >95    3.60  
WWHA6  SP  86,0    ~80    0.70  
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Complex Dd-HAWW 
     HAWW           DD 
Control HeLa cells 
Anti-HA Ab                                  Anti-Dd Ab 
